Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A first-in-class monoclonal antibody is turning heads in lupus treatment. Nipocalimab, which targets the neonatal Fc receptor to reduce harmful autoantibodies, outperformed placebo on multiple lupus response measures at 52 weeks in the phase 2 JASMINE-SLE trial. The drug showed especially strong results in patients with high autoantibody or interferon activity.
Nipocalimab, a first-in-class monoclonal antibody targeting the neonatal Fc receptor (FcRn), has shown meaningful clinical benefit over placebo in patients with moderate-to-severe systemic lupus erythematosus (SLE), according to phase 2 JASMINE-SLE trial data presented at ACR Convergence. The drug works by blocking IgG recycling, which leads to the degradation of both protective and pathogenic antibodies — including the autoantibodies that drive lupus.
The 228-patient trial tested two doses (5 mg/kg and 15 mg/kg) against placebo over 52 weeks. The higher dose was the clear winner, with particularly striking results in patients enriched for specific autoantibodies or high interferon activity.
By the Numbers:
Why it matters: Lupus remains notoriously difficult to treat, and many patients fail standard-of-care therapies. Nipocalimab's FcRn-blocking mechanism offers a novel approach, and its outsized benefit in autoantibody-enriched patients could help clinicians better identify who stands to gain the most — a step toward more personalized lupus care. Phase 3 trials are on the horizon.
